PMID- 14656070
OWN - NLM
STAT- MEDLINE
DCOM- 20040105
LR  - 20201208
IS  - 0022-3069 (Print)
IS  - 0022-3069 (Linking)
VI  - 62
IP  - 11
DP  - 2003 Nov
TI  - Clinical utility of fluorescence in situ hybridization (FISH) in morphologically 
      ambiguous gliomas with hybrid oligodendroglial/astrocytic features.
PG  - 1118-28
AB  - Gliomas with hybrid oligodendroglial/astrocytic features are diagnostically 
      problematic, and our ability to predict tumor behavior is limited. Some likely 
      represent intermingled mixed oligoastrocytomas (MOAs), though precise diagnostic 
      criteria and specific markers for this lesion are lacking. From the files at 
      Washington University (1987-2000), 155 "ambiguous" glioma/intermingled MOA 
      candidates were independently classified and graded by 5 neuropathologists, with 
      consensus-derived pure oligodendrogliomas and astrocytomas excluded from further 
      study. The 90 remaining cases (grades II = 29, III = 44, IV = 17) were analyzed 
      by FISH on formalin-fixed, paraffin-embedded sections. Detectable deletions 
      included combined 1p/19q (9%), solitary 19q (22%), PTEN/DMBT1 (26%), and p16 
      (32%). EGFR amplification was found in 11%. Patients were followed until death 
      (47%) or a median of 3.3 years. Similar to prior glioma series, patient age (p < 
      0.0001) and tumor grade (p < 0.0001) were strongly associated with survival 
      times. EGFR amplification (p = 0.0007) and deletions of PTEN/ DMBT1 (p = 0.016) 
      or p16 (p = 0.014), either individually or as a group (p = 0.04), portended a 
      shorter median survival compared with tumors lacking these alterations. We 
      conclude that 1) distinct genetic subsets are identifiable by FISH in 
      morphologically ambiguous gliomas, and 2) both histological grading and molecular 
      analysis yield prognostically useful information.
FAU - Fuller, Christine E
AU  - Fuller CE
AD  - Department of Pathology, Washington University School of Medicine, St. Louis, 
      Missouri, USA. christine.fuller@stjude.org
FAU - Schmidt, Robert E
AU  - Schmidt RE
FAU - Roth, Kevin A
AU  - Roth KA
FAU - Burger, Peter C
AU  - Burger PC
FAU - Scheithauer, Bernd W
AU  - Scheithauer BW
FAU - Banerjee, Ruma
AU  - Banerjee R
FAU - Trinkaus, Kathryn
AU  - Trinkaus K
FAU - Lytle, Richard
AU  - Lytle R
FAU - Perry, Arie
AU  - Perry A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Neuropathol Exp Neurol
JT  - Journal of neuropathology and experimental neurology
JID - 2985192R
RN  - 0 (Agglutinins)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (DMBT1 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.1.3.2 (Phosphoric Monoester Hydrolases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Agglutinins
MH  - Astrocytoma/*diagnosis/metabolism/pathology
MH  - Brain Neoplasms/*diagnosis/epidemiology/metabolism
MH  - Calcium-Binding Proteins
MH  - Child
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 1
MH  - Chromosomes, Human, Pair 19
MH  - Cohort Studies
MH  - DNA-Binding Proteins
MH  - Demography
MH  - Diagnosis, Differential
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Deletion
MH  - Genes, erbB-1/genetics/physiology
MH  - Genes, p16
MH  - Glioma/*diagnosis/metabolism/pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Oligodendroglioma/*diagnosis/metabolism/pathology
MH  - PTEN Phosphohydrolase
MH  - Phosphoric Monoester Hydrolases/genetics/metabolism
MH  - Receptors, Cell Surface/genetics/metabolism
MH  - Survival Analysis
MH  - Tumor Suppressor Proteins/genetics/metabolism
EDAT- 2003/12/06 05:00
MHDA- 2004/01/06 05:00
CRDT- 2003/12/06 05:00
PHST- 2003/12/06 05:00 [pubmed]
PHST- 2004/01/06 05:00 [medline]
PHST- 2003/12/06 05:00 [entrez]
AID - 10.1093/jnen/62.11.1118 [doi]
PST - ppublish
SO  - J Neuropathol Exp Neurol. 2003 Nov;62(11):1118-28. doi: 10.1093/jnen/62.11.1118.